COG Phase I Consortium

Arcadia, California 91006-3776

0 studies enrolling now · 10 studies all time

What they study most

Acute Undifferentiated Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia

Studies at this site

• IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor — Completed
• Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes — Completed
• Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy — Completed
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas — Completed
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia — Completed
• Bevacizumab in Treating Young Patients With Refractory Solid Tumors — Completed
• Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia — Completed
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas — Completed
• Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia — Completed
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors — Completed